Bial - Portela C S.A.

REal-life ON PARKinson's - ITaly (REONPARK-IT)

Role: lead

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

Role: lead

Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide

Role: lead

Anti-epileptogenic Effects of Eslicarbazepine Acetate

Role: lead

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Role: lead

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Role: lead

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Role: lead

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Role: lead

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

Role: lead

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Role: lead

OpiCapone Effect on Motor Fluctuations and pAiN

Role: lead

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Role: lead

OpicApone Sleep dISorder

Role: lead

Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Role: lead

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.

Role: lead

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Role: lead

Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

Role: lead

Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)

Role: lead

Safety and Efficacy of BIA 5-1058 in PAH

Role: lead

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

Role: lead